September 1, 1997Expert Opinion on Investigational Drugs
Tirofiban: an investigational plateletglycoprotein IIb/IIIa receptor antagonist
Key result
In clinical trials, tirofiban decreased the odds of recurrent ischaemia, myocardial infarction, or death by 36% at 48 hours compared to heparin in patients with unstable angina.
Why the study?
Does tirofiban reduce ischemic events in patients with unstable angina and high-risk PTCA?
Population
Patients with unstable angina and high-risk percutaneous transluminal coronary angioplasty (PTCA)
Comparison
Tirofiban administered as an intravenous infusion vs Heparin (in unstable angina management)
Design
Review
Follow-up
up to 30 days
Authors
Discussion
Loading...
Member takes
Implication
Supports early tirofiban consideration in unstable angina; leaves open its role in high-risk PTCA and modern regimens.
Structured PICO
Does tirofiban reduce ischemic events in patients with unstable angina and high-risk PTCA?
P
Population
Patients with unstable angina and high-risk percutaneous transluminal coronary angioplasty (PTCA)
I
Intervention
Tirofiban administered as an intravenous infusion
C
Comparator
Heparin (in unstable angina management)
O
Outcome
Composite of recurrent ischaemia, myocardial infarction, or deathcomposite
Main Result
Effect estimate: 36% reduction in odds
Tirofiban, a GPIIb/IIIa inhibitor, significantly reduces ischemic events in patients with unstable coronary syndromes and those undergoing high-risk PTCA without significantly increasing major bleeding.
Cite This Study
Kumar et al. (1997) conducted a review in Unstable coronary syndromes and high-risk PTCA. Tirofiban vs. Heparin was evaluated on Recurrent ischaemia, myocardial infarction, or death at 48 h (36% reduction in odds). In clinical trials, tirofiban decreased the odds of recurrent ischaemia, myocardial infarction, or death by 36% at 48 hours compared to heparin in patients with unstable angina.